> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-15/
- Published: 2020-03-08T12:00:00.000Z
- Updated: 2026-09-14T16:06:10.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5146280

[**Draft Guide on Including Older Patients in Trials**](https://www.fdaweb.com/draft-guide-on-including-older-patients-in-trials/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Inclusion of Older Adults in Cancer Clinical Trials.” 03/06/2020  

[**Policy for Coronavirus Testing Labs**](https://www.fdaweb.com/policy-for-coronavirus-testing-labs/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency.” 03/06/2020  

[**CDER Regulatory Project Management Site Tours**](https://www.fdaweb.com/cder-regulatory-project-management-site-tours/)  
*Federal Register* notice: CDER announces its decision to continue Regulatory Project Management Site Tours and Regulatory Interaction Program. 03/06/2020  

[**Electrical Stimulation Device Ban**](https://www.fdaweb.com/electrical-stimulation-device-ban/)  
*Federal Register* notice: FDA finalizes a ban on electrical stimulation devices for self-injurious or aggressive behavior. 03/06/2020  

[**Exocrine Pancreatic Insufficiency NDA Guide Withdrawn**](https://www.fdaweb.com/exocrine-pancreatic-insufficiency-nda-guide-withdrawn/)  
*Federal Register* notice: FDA withdraws its 2006 guidance entitled “Exocrine Pancreatic Insufficiency Drug Products — Submitting NDAs.” 03/05/2020  

[**Regulatory Review Period for Ingrezza**](https://www.fdaweb.com/regulatory-review-period-for-ingrezza/)  
*Federal Register* notice: FDA determines the regulatory review period for patent extension purposes for Neurocrine Biosciences’ Ingrezza (valbenazine tosylate). 03/05/2020  

[**Q & A Guide on ‘Deemed to be a License’**](https://www.fdaweb.com/q-a-guide-on-deemed-to-be-a-license/)  
*Federal Register* notice: FDA makes available a guidance entitled “The ‘Deemed To Be a License’ Provision of the BPCI Act: Questions and Answers.” 03/05/2020  

[**Purple Book Enhancements in First Phase**](https://www.fdaweb.com/purple-book-enhancements-in-first-phase/)  
*Federal Register* notice: FDA announces the completion of the first phase of its enhanced Purple Book for biologics. 03/05/2020  

[**Info Collection on GMPs for Medicated Feeds**](https://www.fdaweb.com/info-collection-on-gmps-for-medicated-feeds/)  
*Federal Register* notice: FDA seeks comments on an information collection extension for medicated feed GMPs. 03/04/2020  

[**Regulatory Review Period for Kyowa Asthma Drug**](https://www.fdaweb.com/regulatory-review-period-for-kyowa-asthma-drug/)  
*Federal Register* notice: FDA determines the regulatory review period for patent extension purposes for Kyowa Hakko Kirin’s Fasenra (benralizumab). 03/04/2020  

[**Guide on Contacts Performance Criteria**](https://www.fdaweb.com/guide-on-contacts-performance-criteria/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Soft (Hydrophilic) Daily Wear Contact Lenses — Performance Criteria for Safety and Performance Based Pathway.” 03/04/2020